ISU
Home
ISURF/OIPTT
Home
ISURFtech
Home
Advanced
Search
RSS
Feeds
Haemophilus Influenzae Immunogen
Category(s):
For Information, Contact:
Dario Valenzuela
Senior Commercialization Manager, Life Sciences
515-294-4740
licensing@iastate.edu
Web Published:
7/19/2017
ISURF #
4475
Summary:
A powerful antigenic protein for the development of a vaccine against Nontypeable Haemophilus Influenzae

Development Stage:

Description:
Nontypeable Haemophilus Influenzae (NTHI) is a significant respiratory pathogen associated with millions of yearly middle ear infections in young children and with many cases of pneumonia in the elderly. Currently, there is no efficacious vaccine against Nontypeable Haemophilus Influenzae. By comparing children prone to ear infections with non-prone children, the ISU contributors discovered that non-prone children differed from prone children by having a strong antibody response against a specific Nontypeable Haemophilus Influenzae protein. This discovery with its subsequent validation could be the basis for the development of an effective commercial vaccine against the pathogen.

Advantage:
• May enable the first commercial Nontypeable Haemophilus Influenzae vaccine
• Strong in vivo protection in mice againts many strains
• Highly conserved protein immunogen

Patent Information:
*To see the full version of the patent(s), follow the link below, then click on "Images" button.

Patent:
Patent(s) applied for

Direct Link: